This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mackey, J. R. Articles by Cass, C. E. Search for Related Content PubMed PubMed Citation Articles by Mackey, J. R. Articles by Cass, C. E. Related Collections Key Article

Immunohistochemical Variation of Human Equilibrative Nucleoside Transporter 1 Protein in Primary Breast Cancers¹

Departments of Experimental Oncology [L. L. J., M. L. C., C. L. S.], Medicine [J. R. M., S. L. K.], and Pathology [L. B., R. W. C.], Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2 Canada; Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic [M. V.]; School of Biochemistry and Molecular Biology, University of Leeds, Leeds, LS2 9JT United Kingdom [S. A. B.]; Departments of Physiology [J. D. Y], Biochemistry [C. E. C.], and Oncology [J. R. M., S. L. K., C. E. C.], University of Alberta, Edmonton, Alberta, T6G 2R7 Canada

Gemcitabine and capecitabine are nucleoside analogues used in chemotherapy strategies for the treatment of breast cancer. We previously demonstrated that deficiency in hENT1, the most abundant and widely distributed plasma membrane nucleoside transporter in human cells, confers high-level resistance to gemcitabine toxicity in vitro, whereas the relationship between hENT1 activity and capecitabine toxicity is unknown. To determine the relationship between capecitabine cytotoxicity and hENT1 abundance, cultured MDA-MB-435s human mammary carcinoma cells were exposed to graded concentrations of the capecitabine metabolites, 5'-deoxy-5-fluorouridine or 5-fluorouracil, in the presence and absence of nitrobenzylmercaptopurine ribonucleoside (NBMPR), a tight-binding inhibitor of hENT1. The presence of NBMPR reduced the cytotoxic effects of 5'-deoxy-5-fluorouridine, indicating that hENT1 also enabled cellular uptake of this capecitabine metabolite by breast cancer cells. We report here the development of an immunohistochemical method to assess the hENT1 abundance of malignant cells in solid tumors. Frozen sections of 33 primary breast cancers were stained with monoclonal antibodies raised against a synthetic peptide derived from the large intracellular loop of hENT1, and staining intensity was scored on a 0–4+ scale. hENT1 staining intensity varied markedly among breast samples (4 with score 0, 5 with score 1+, 7 with score 2+, 14 with score 3+, 3 with score 4+), suggesting that at least 9 of the tumors were hENT1 deficient. We conclude that because hENT1 deficiency has previously been associated with nucleoside drug resistance, immunohistochemical staining of hENT1 warrants further study as a predictive tool for guiding the appropriate use of gemcitabine and capecitabine in the treatment of breast cancer.

Key Article

Membrane Transport of Chemotherapeutics and Drug Resistance: Beyond the ABC Family of Exporters to the Role of Carrier-mediated Processes

I. David Goldman
Clin. Cancer Res. 2002 8: 4-6. [Full Text] [PDF]

This article has been cited by other articles:

				D. Santini, G. Perrone, B. Vincenzi, R. Lai, C. Cass, R. Alloni, C. Rabitti, A. Antinori, F. Vecchio, S. Morini, et al. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer Ann. Onc., April 1, 2008; 19(4): 724 - 728. [Abstract] [Full Text] [PDF]

				V. L. Damaraju, A. N. Elwi, C. Hunter, P. Carpenter, C. Santos, G. M. Barron, X. Sun, S. A. Baldwin, J. D. Young, J. R. Mackey, et al. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney Am J Physiol Renal Physiol, July 1, 2007; 293(1): F200 - F211. [Abstract] [Full Text] [PDF]

				J. Spratlin, R. Sangha, D. Glubrecht, L. Dabbagh, J. D. Young, C. Dumontet, C. Cass, R. Lai, and J. R. Mackey The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma Clin. Cancer Res., October 15, 2004; 10(20): 6956 - 6961. [Abstract] [Full Text] [PDF]

				L. Dabbagh, R. W. Coupland, C. E. Cass, and J. R. Mackey Correspondence Re: J. R. Mackey et al., Immunohistochemical Variation of Human Equilibrative Nucleoside Transporter 1 Protein in Primary Breast Cancers. Clin. Cancer Res., 8: 110ndash;116, 2002. Clin. Cancer Res., August 1, 2003; 9(8): 3213 - 3214. [Full Text] [PDF]

				M. Molina-Arcas, B. Bellosillo, F. J. Casado, E. Montserrat, J. Gil, D. Colomer, and M. Pastor-Anglada Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia Blood, March 15, 2003; 101(6): 2328 - 2334. [Abstract] [Full Text] [PDF]